Literature DB >> 16920484

Determination of the inhibitory activity and biological half-live of soluble CD83: comparison of wild type and mutant isoforms.

Elisabeth Zinser1, Matthias Lechmann, Antje Golka, Barry Hock, Alexander Steinkasserer.   

Abstract

A soluble form of CD83 ("sCD83") has been shown to block DC-mediated T cell stimulation in vitro and an immunosuppressive role has also been shown in vivo using an experimental-autoimmune-encephalomyelits (EAE) model. Using recombinant mutational analyses, recently, we could show that sCD83 forms a homo-dimer, whereby four cysteines are involved in the intra-molecular disulfide bonds and the fifth cysteine is responsible for the inter-molecular bridging of the two molecules. Further studies revealed that the two CD83-isoforms, i.e. the dimer and the monomer, have a similar inhibitory capacity when tested in vitro. Here we show that the biological (in vivo) half-life of the two sCD83 isoforms is comparable and was between 2 and 3h. In addition, using the EAE-model, we were able to show that a monomeric-mutant isoform of soluble CD83 has a similar inhibitory activity in vivo when compared with a dimeric-wildtype isoform.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16920484     DOI: 10.1016/j.imbio.2006.05.009

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  3 in total

Review 1.  Dendritic cell CD83: a therapeutic target or innocent bystander?

Authors:  Charlene M Prazma; Thomas F Tedder
Journal:  Immunol Lett       Date:  2007-10-29       Impact factor: 3.685

2.  Gene expression profiling of precursor T-cell lymphoblastic leukemia/lymphoma identifies oncogenic pathways that are potential therapeutic targets.

Authors:  Y-W Lin; P D Aplan
Journal:  Leukemia       Date:  2007-04-12       Impact factor: 11.528

3.  Endogenous Expression of the Human CD83 Attenuates EAE Symptoms in Humanized Transgenic Mice and Increases the Activity of Regulatory T Cells.

Authors:  Elisabeth Zinser; Ronald Naumann; Andreas B Wild; Julia Michalski; Andrea Deinzer; Lena Stich; Christine Kuhnt; Alexander Steinkasserer; Ilka Knippertz
Journal:  Front Immunol       Date:  2019-06-25       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.